Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer

被引:60
作者
Rasch, Morten G. [1 ]
Lund, Ida K. [1 ]
Almasi, Charlotte E. [1 ]
Hoyer-Hansen, Gunilla [1 ]
机构
[1] Rigshosp, Finsen Lab, Copenhagen Bioctr, Sect 3735, DK-2200 Copenhagen N, Denmark
来源
FRONTIERS IN BIOSCIENCE-LANDMARK | 2008年 / 13卷
关键词
uPAR cleavage; uPA; monoclonal antibodies; TR-FIA; prognosis; diagnosis; cancer; plasminogen activation; review;
D O I
10.2741/3186
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The cellular receptor for urokinase, uPAR, localizes its ligand, uPA, and thereby the plasminogen activation, to the cell surface. uPA also cleaves uPAR, liberating the ligand-binding domain I, and thereby inactivates the binding potential of uPAR for both uPA and vitronectin. The uPA-catalyzed cleavage of uPAR is fast on the cell surface, when uPA is bound to a neighboring uPAR molecule. uPAR can be shed from the cell surface. However, the soluble form cannot be cleaved by uPA. Glycolipid-anchored and soluble forms of intact, uPAR(I-III), and cleaved receptor, uPAR(II-III) and uPAR(I), have been identified in tissue and body fluids. It is well-established, that the total amount of all uPAR forms is a strong prognostic marker in different types of cancer. Using immunoassays, measuring the individual uPAR forms, has revealed that the cleaved uPAR forms are even stronger prognostic markers and have diagnostic utility. This review will focus on the mechanism of uPAR cleavage and the functional consequences, as well as the clinical applicability of cleaved uPAR forms.
引用
收藏
页码:6752 / 6762
页数:11
相关论文
共 94 条
  • [61] The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R
    Resnati, M
    Pallavicini, I
    Wang, JM
    Oppenheim, J
    Serhan, CN
    Romano, M
    Blasi, F
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (03) : 1359 - 1364
  • [62] Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect
    Resnati, M
    Guttinger, M
    Valcamonica, S
    Sidenius, N
    Blasi, F
    Fazioli, F
    [J]. EMBO JOURNAL, 1996, 15 (07) : 1572 - 1582
  • [63] Urokinase-type plasminogen activator (uPA) and its receptor (uPAR):: Development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo
    Reuning, U
    Sperl, S
    Kopitz, C
    Kessler, H
    Krüger, A
    Schmitt, M
    Magdolen, V
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (19) : 1529 - 1543
  • [64] Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients.: An EORTC-receptor and Biomarker Group collaboration
    Riisbro, R
    Christensen, IJ
    Nielsen, HJ
    Brünner, N
    Nilbert, A
    Fernebro, E
    [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2005, 20 (02) : 93 - 102
  • [65] Riisbro R, 2002, J CLIN LIGAND ASSAY, V25, P53
  • [66] Riisbro R, 2002, CLIN CANCER RES, V8, P1132
  • [67] The urokinase receptor as a potential target in cancer therapy
    Romer, J
    Nielsen, BS
    Ploug, M
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (19) : 2359 - 2376
  • [68] CELL-INDUCED POTENTIATION OF THE PLASMINOGEN ACTIVATION SYSTEM IS ABOLISHED BY A MONOCLONAL-ANTIBODY THAT RECOGNIZES THE NH2-TERMINAL DOMAIN OF THE UROKINASE RECEPTOR
    RONNE, E
    BEHRENDT, N
    ELLIS, V
    PLOUG, M
    DANO, K
    HOYERHANSEN, G
    [J]. FEBS LETTERS, 1991, 288 (1-2) : 233 - 236
  • [69] QUANTITATION OF THE RECEPTOR FOR UROKINASE PLASMINOGEN-ACTIVATOR BY ENZYME-LINKED-IMMUNOSORBENT-ASSAY
    RONNE, E
    BEHRENDT, N
    PLOUG, M
    NIELSEN, HJ
    WOLLISCH, E
    WEIDLE, U
    DANO, K
    HOYERHANSEN, G
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1994, 167 (1-2) : 91 - 101
  • [70] Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics
    Schmiedeberg, N
    Schmitt, M
    Röl, C
    Truffault, V
    Sukopp, M
    Bürgle, M
    Wilhelm, OG
    Schmalix, W
    Magdolen, V
    Kessler, H
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (23) : 4984 - 4994